Institutional Project 2026-2030

PDF - 7.71 MB

A Bold Ambition

“Our 2026–2030 institutional plan is not just a roadmap: it concretely reflects our commitment to patients, our staff, and society. Achieving an 80% cure rate by 2040 requires us to accelerate our efforts to implement our vision at every level: better prevention, faster diagnosis, and innovation at every stage and throughout the entire care continuum. “This initiative gives us the means to act sustainably by strengthening our scientific excellence, the reliability of patient care pathways, our international reach, and a model capable of supporting innovation for the benefit of all,” states Prof. Fabrice Barlesi, Executive Director of Gustave Roussy.

In an environment marked by an increasing pace of therapeutic innovations and the need for responsible use of resources, Gustave Roussy reaffirms its commitment through an integrated oncology model that combines care, research, commercialization, and education. This new institutional plan is based on four guiding principles that will steer the Institute’s actions over the next five years.

Four Major Strategic Priorities for 2026–2030

1. Implementing personalized care pathways and “appropriate care”

The Institute is focusing its efforts on the key phases of the care pathway where its expertise is critical. This approach introduces the concept of “appropriate care,” aimed at ensuring the relevance and proportionality of treatments, including therapeutic de-escalation when necessary. It also calls for the expansion of personalized prevention and rapid diagnosis programs (Interception and Instadiag), and strengthening coordination with healthcare partners to ensure local follow-up care after the acute phase of the disease, using digital tools such as the Shared Medical Record.

2. Intensifying research with significant societal impact and its dissemination

With the support of its Foundation, Gustave Roussy is consolidating its integrative research model, prioritizing the most common cancers and the most aggressive tumors. Particular emphasis will be placed on cancers affecting young people (ages 25–45) and aggressive gastrointestinal cancers. The goal is to reach 60 research teams and to enroll 1,000 patients each year in early-phase trials through the clinical research platform, in collaboration with DITEP (Department of Therapeutic Innovation and Early-Phase Trials). The commercialization of innovations developed by Gustave Roussy’s teams will be strengthened with the support of Gustave Roussy Transfert’s expertise and the partnership with the Paris-Saclay Cancer Cluster. Finally, the mission to provide training and disseminate knowledge in oncology is reaffirmed, both in France and internationally.

3. Accelerating Digital Transformation and AI

A major new feature of this plan is the integration of AI, which will serve as a concrete lever for precision medicine and saving clinical time. The Institute plans to deploy decision-support tools while ensuring that human validation remains an integral part of the medical diagnostic process. By 2026, Gustave Roussy will complete the modernization of its information system with the full migration of its DxCare electronic health record system and the deployment of Doctolib. Several key projects are currently underway: the GOLDEN health data warehouse, which consolidates data from more than 400,000 patients; work on generative AI conducted with IHU PRISM; and the exploration of new AI agents designed to accelerate research.

4. Securing Resources to Match Our Ambitions

In response to pressures in the healthcare professions, and to enhance its appeal and retain its teams, the Institute is focusing on a competitive compensation policy, the development of training programs, and improvements to the quality of life at work. Financially, the goal is to maintain self-financing capacity, increase philanthropic fundraising, and support the growth of subsidiaries responsible for commercialization and international development. Real estate development and infrastructure modernization will continue with the renovation of the historic building and the construction of three new buildings—including those dedicated to research and teaching—by 2028.

A vision driven by the community

Developed between March and November 2025, the 2026–2030 Institutional Plan is the result of a broad collaborative effort involving all of the Institute’s professionals. More than 150 volunteers participated in collaborative workshops, supplemented by an internal survey and co-writing groups that included the Patients and Caregivers Collective. In total, nearly 1,000 people were involved in shaping this new institutional plan—representing about a quarter of the workforce—without compromising the founding spirit of the 2020–2030 Institutional Strategic Plan.

“The goal was to rethink the guidelines, update them, and anchor them in a forward-looking perspective by relying on a fully participatory approach,” emphasizes Sylvain Ducroz, Deputy Director General of Gustave Roussy. “This project is a collective commitment to ensuring that Gustave Roussy’s excellence benefits as many people as possible.”

2025 Results in Figures

In 2025, more than 24,000 new patients—and more than 52,000 patients in total, including 2,700 children and adolescents—were treated at Gustave Roussy. More than 6,100 patients were enrolled in clinical trials, confirming the institute’s role as a driving force in translational research; nearly 500 of these patients benefited from early access to innovative therapies through the DITEP. Activity indicators (+5%) reflect an enhanced capacity to admit, diagnose, and treat an ever-increasing number of patients, sometimes in highly complex situations. The institute’s total budget amounts to 600 million euros, of which 150 million are dedicated to research and 53 million to ambitious investments. Research conducted at the Institute has resulted in more than 1,200 publications, including over 150 in high-impact international journals. In total, Gustave Roussy Transfert has co-founded 21 companies, including three new ones in 2025, all stemming from research conducted at Gustave Roussy.

All of these advances have a direct and tangible impact on the lives of patients and their loved ones.

Institutional Project 2026-2030

PDF - 7.71 MB